Clinical trial Recruiting at 1 site Observational Ages 18 and up

How the triglyceride–glucose (TyG) index relates to heart artery imaging in non‑diabetic adults with early coronary artery disease

Official title: Impact of Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients

Run by Sohag University · NCT07154186 · Data updated 2026-11-12

This study will see if the triglyceride–glucose (TyG) index helps explain angiographic patterns in non‑diabetic adults who develop coronary artery disease at younger ages.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment180 (estimated)
SponsorSohag University
Academic / other
Locations1 site (Sohag)
StatusRecruiting
StartedSeptember 4, 2025
Main results expectedFebruary 1, 2026
Study endsFebruary 1, 2026
Registry record updatedSeptember 5, 2025
Trial IDNCT07154186 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older who are non‑diabetic with angiographically confirmed premature coronary artery disease (before age 55 in men and 65 in women), without prior coronary revascularization and without severe hepatic or renal dysfunction.

Probably not a fit

People with known diabetes, prior coronary revascularization, severe liver or kidney disease, active cancer, autoimmune or systemic inflammatory disorders, or those already on triglyceride‑lowering drugs are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study of non‑diabetic patients with premature coronary artery disease confirmed by coronary angiography. Investigators will calculate the TyG index from fasting triglyceride and glucose levels and compare it with angiographic lesion patterns and severity. Patients with known diabetes, prior revascularization, severe liver/kidney dysfunction, malignancy, autoimmune or systemic inflammatory disease, or current triglyceride‑lowering therapy are excluded. The work is conducted at Sohag University and aims to link a low‑cost blood marker of insulin resistance to early atherosclerotic changes on angiography.

Why it matters

Potential benefit: If successful, the TyG index could offer a simple, low‑cost blood marker to help identify insulin‑resistance–related artery disease patterns and guide earlier management in non‑diabetic patients.

How similar studies have gone: Prior observational studies have reported links between higher TyG index values and more severe coronary atherosclerosis, but prospective and interventional evidence remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥18 years old.
* Both sexes.
* Non-diabetic patients \[no history of diabetes, hemoglobin A1C (HbA1C) \< 6.5%, fasting glucose \< 126 mg/dL\].
* Confirmed diagnosis of coronary artery disease (CAD) by coronary angiography.

Exclusion Criteria:

* Known diabetes mellitus (type 1 or type 2).
* Previous history of coronary revascularization.
* Severe hepatic or renal dysfunction \[alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥ 5× upper limit of normal (ULN), estimated glomerular filtration rate (eGFR)\< 30 mL/min/1.73 m²\].
* Malignant disease, autoimmune disease, or systemic inflammatory disorders.
* Current use of triglyceride-lowering medications.

Where it's running

  • Sohag University
    Sohag, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.